TVAX Biomedical to Present at 15th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference

LENEXA, KS--(Marketwire - February 04, 2013) - TVAX Biomedical, a clinical stage development company advancing its proprietary T cell-based immunotherapy for the treatment of cancer, today announced that the company will present at the 15th Annual BIO CEO & Investor Conference. The conference will take place February 11-12, 2013 at the Waldorf Astoria Hotel in New York City. Phil Haworth, Ph.D., chief executive officer of TVAX, will present a corporate update on Monday, February 11, 2013 at 1:45 p.m. (Eastern) in the Park South presentation room.

Dr. Haworth will also be available for one-on-one meetings with investors during the conference. If you are interested in meeting with Dr. Haworth, please contact Stephanie Diaz of Vida Strategic Partners at 415-675-7401 or sdiaz@vidasp.com.

About TVAX Biomedical

TVAX Biomedical is a clinical stage development company advancing its targeted T cell-based immunotherapy for the treatment of cancer. The company’s proprietary therapeutic approach offers the promise of improved clinical outcomes, low toxicity and the potential for fundamentally changing the way cancer is treated. TVAX Immunotherapy is a unique personalized “killer” T cell treatment. This treatment has demonstrated the potential to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. A key distinction between TVAX and other cancer immunotherapy companies is TVAX’s patented “killer” T cell treatment. The power of “killer” T cells is their demonstrated ability to kill cancer cells, including cancer stem cells, and cause significant numbers of objective clinical responses in treated patients.

The company’s lead candidates, which are focused on treating brain and kidney cancer, are supported by positive Phase 2 clinical data, as well as extensive preclinical and Phase 1 safety studies. TVAX plans to initiate a Phase 2b study in newly diagnosed glioblastoma patients during Q3 2013. Additionally, FDA has authorized the company to initiate pivotal Phase 3 clinical trials in both brain and kidney cancer. In addition to these lead programs, extensive proof-of-concept and safety data have been generated to support the use of the TVAX approach in several other cancer treatment indications. As part of its ongoing strategy, the company is seeking to establish corporate alliances to support the development of TVAX Immunotherapy.

For more information visit: www.tvaxbiomedical.com